Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736148 | 0.86 | ATM (0.54) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL3729615 | 0.86 | CTSL (0.50) | ATMCTSLCTSKCTSSCTSB | |
| SCHEMBL3739472 | 0.85 | ATM (0.53) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL3728346 | 0.84 | CTSK (0.55) | ATMCTSLCTSKCTSSCTSB | |
| SCHEMBL7168072 | 0.84 | ATM (0.51) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL3726951 | 0.83 | ATM (0.50) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL7675256 | 0.83 | ATM (0.50) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL3733642 | 0.82 | CTSD (0.49) | ATMCTSDCTSLCTSKCTSS | |
| SCHEMBL20885259 | 0.81 | SYK (0.59) | ATMCTSLCTSKCTSSCTSB | |
| SCHEMBL11657615 | 0.81 | SYK (0.59) | ATMCTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | AB, Medivir (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-1150956-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| EP-1121366-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| EP-1054891-A1 | PRODRUGS | MEDIVIR AB (SE) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047561-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999041275-A1 | PRODRUGS | MEDIVIR AB (SE) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | ATM 4574/4885CTSD 1981/4885CTSL 756/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | ATM 4246/4885CTSD 3295/4885CTSL 483/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | ATM 4574/4885CTSD 1981/4885CTSL 756/4885 |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, CBR1, GAR1 | ATM 4410/4885CTSD 3741/4885CTSL 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.